Werewolf Therapeutics (HOWL) Competitors $0.81 -0.11 (-11.69%) As of 12:03 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOWL vs. CTNM, CKPT, LFVN, NMRA, CRGX, AMRN, TNGX, OCGN, KOD, and CGCShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Contineum Therapeutics (CTNM), Checkpoint Therapeutics (CKPT), LifeVantage (LFVN), Neumora Therapeutics (NMRA), CARGO Therapeutics (CRGX), Amarin (AMRN), Tango Therapeutics (TNGX), Ocugen (OCGN), Kodiak Sciences (KOD), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Contineum Therapeutics Checkpoint Therapeutics LifeVantage Neumora Therapeutics CARGO Therapeutics Amarin Tango Therapeutics Ocugen Kodiak Sciences Canopy Growth Contineum Therapeutics (NASDAQ:CTNM) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Does the MarketBeat Community prefer CTNM or HOWL? Werewolf Therapeutics received 23 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 70.83% of users gave Werewolf Therapeutics an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesWerewolf TherapeuticsOutperform Votes3470.83% Underperform Votes1429.17% Is CTNM or HOWL more profitable? Contineum Therapeutics has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Contineum Therapeutics' return on equity of -49.92% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% Werewolf Therapeutics -578.80%-58.83%-38.45% Does the media favor CTNM or HOWL? In the previous week, Werewolf Therapeutics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 2 mentions for Werewolf Therapeutics and 0 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score. Company Overall Sentiment Contineum Therapeutics Neutral Werewolf Therapeutics Neutral Do institutionals & insiders hold more shares of CTNM or HOWL? 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 21.1% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, CTNM or HOWL? Contineum Therapeutics has higher revenue and earnings than Werewolf Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M3.27$22.72M-$4.90-1.29Werewolf Therapeutics$1.89M19.16-$37.37M-$1.66-0.49 Do analysts rate CTNM or HOWL? Contineum Therapeutics currently has a consensus price target of $24.80, suggesting a potential upside of 292.41%. Werewolf Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 1,017.04%. Given Werewolf Therapeutics' higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryContineum Therapeutics beats Werewolf Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.12M$6.77B$5.57B$7.57BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-0.537.0222.8518.16Price / Sales19.16199.24362.4886.29Price / CashN/A65.6738.1634.64Price / Book0.265.946.514.01Net Income-$37.37M$142.37M$3.21B$247.18M7 Day Performance-24.70%-8.95%-6.09%-5.86%1 Month Performance-29.32%-9.85%-0.35%-6.95%1 Year Performance-86.62%-14.80%6.32%-3.71% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics1.981 of 5 stars$0.81-11.7%$9.00+1,017.0%-84.9%$36.12M$1.89M-0.5340Gap DownCTNMContineum Therapeutics1.5621 of 5 stars$7.76+8.2%$24.80+219.6%N/A$200.77M$50M-1.5831Positive NewsCKPTCheckpoint Therapeutics2.3738 of 5 stars$4.05-0.5%$4.33+7.0%+110.4%$197.77M$47,000.00-2.2010Earnings ReportAnalyst ForecastLFVNLifeVantage3.231 of 5 stars$15.56+0.6%$30.50+96.0%+148.1%$195.29M$212.15M27.79260Positive NewsNMRANeumora Therapeutics2.9983 of 5 stars$1.20+6.2%$10.14+745.2%-93.2%$194.38MN/A-0.64108Analyst ForecastCRGXCARGO Therapeutics3.137 of 5 stars$4.20+0.5%$15.00+257.1%-79.8%$193.42MN/A-0.99116Positive NewsAMRNAmarin0.9507 of 5 stars$0.46+1.6%N/A-56.4%$190.76M$228.61M-5.16360Analyst ForecastGap DownTNGXTango Therapeutics1.6989 of 5 stars$1.74-1.1%$12.33+608.8%-81.9%$188.11M$42.07M-1.4790Short Interest ↑Gap DownOCGNOcugen1.3077 of 5 stars$0.64+5.4%$6.33+893.6%-50.1%$186.13M$4.06M-3.5480Positive NewsGap DownKODKodiak Sciences4.0292 of 5 stars$3.52+7.3%$8.00+127.3%-38.3%$185.24MN/A-0.9690Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCGCCanopy Growth2.0119 of 5 stars$1.16+4.5%$2.00+72.4%-87.4%$183.99M$276.75M-0.313,150Gap Down Remove Ads Related Companies and Tools Related Companies Contineum Therapeutics Alternatives Checkpoint Therapeutics Alternatives LifeVantage Alternatives Neumora Therapeutics Alternatives CARGO Therapeutics Alternatives Amarin Alternatives Tango Therapeutics Alternatives Ocugen Alternatives Kodiak Sciences Alternatives Canopy Growth Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOWL) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOWL Stock Free HOWL Stock Alerts